Viewpoint: activin signalling inhibitors for the treatment of pulmonary arterial hypertension

Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension

(2023) Marius M. Hoeper et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial

(2023) Rogerio Souza et al.   EUROPEAN RESPIRATORY JOURNAL

Treatment of pulmonary arterial hypertension: recent progress and a look to the future

(2023) Marc Humbert et al.   Lancet Respiratory Medicine

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

(2022) Marc Humbert et al.   EUROPEAN HEART JOURNAL

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

(2022) Marc Humbert et al.   EUROPEAN RESPIRATORY JOURNAL

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension

(2022) Marc Humbert et al.   EUROPEAN RESPIRATORY JOURNAL

The evolving landscape of pulmonary arterial hypertension clinical trials

(2022) Jason Weatherald et al.   LANCET

Sotatercept for the Treatment of Pulmonary Arterial Hypertension

(2021) Marc Humbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

COMPERA 2.0: A refined 4-strata risk assessment model for pulmonary arterial hypertension

(2021) Marius M. Hoeper et al.   EUROPEAN RESPIRATORY JOURNAL

External validation of a refined 4-strata risk assessment score from the French pulmonary hypertension Registry

(2021) Athénaïs Boucly et al.   EUROPEAN RESPIRATORY JOURNAL

Targeting Transforming Growth Factor Beta Receptors in Pulmonary Hypertension

(2020) Christophe Guignabert et al.   EUROPEAN RESPIRATORY JOURNAL

Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives

(2018) Marc Humbert et al.   EUROPEAN RESPIRATORY JOURNAL

An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry

(2012) Raymond L. Benza et al.   CHEST